Claims of a positive effect in a small subgroup of patients are statistically meaningless, experts say.
Antisense oligonucleotides can flip expression of tau from the three-repeat to the four-repeat form. These ASOs triggered tau aggregation and behavioral problems.
Imaging study correlated four patterns of neurodegeneration that map to two neural networks with certain behavioral symptoms.
Four researchers received awards totaling $350,000 for their contributions to Alzheimer’s research.
Researchers may soon add another imaging agent to their tool kit—one that tracks synapse loss.
At Keystone, researchers also linked the receptor to microglial homeostasis and migration, and resolved lingering questions about TREM2’s role in plaque clearance.
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
People who report a prior head injury have no more chance of getting Alzheimer’s than the rest of the population, but they may be at higher risk for Parkinson’s.
Held July 24 to 28 in Toronto, the Alzheimer’s Association International Conference showcased a field in transformation. At the clinical level, groups from Europe, North America, and Japan are attempting to coalesce around new ways to recruit preclinical populations for large observational and trial platforms for late-onset AD, while the smaller but more established DIAN initiative is growing into a worldwide movement. At the biological level, research is set to expand thanks to funding increasing in response to national plans. Health economics research is pressing in. Topically, tau ruled the roost, though genetics, vascular contributions to dementia, and efforts to define ever-earlier stages of the decades-long disease continuum advanced, as well. On the clinical trials front, the only Phase 3 study appears to have been largely a bust, while some Phase 1 presentations of new antibodies, BACE inhibitors, and a small-molecule tau modifier drew quiet praise. Our coverage starts with the TauRx trial, and will move on to other topics in the next two weeks.
Plaques, tangles, and now synapses? A new PET ligand on the horizon binds a protein found in synaptic vesicles. With all the makings of a solid PET tracer, the compound appears to track synaptic density in monkeys and in people, and easily detects synapse loss in patients with epilepsy. It now stands poised for its debut in Alzheimer’s disease and other disorders that tear down connections between neurons.
With PET, researchers can now image the neurofibrillary tangles and amyloid plaques of Alzheimer’s disease in the living brain. In cognitively healthy elderly, the two pathologies occur independently for the most part, but they do correlate with each other in certain key brain regions, according to a new study. In particular, pathological tau in the inferior lateral temporal cortex tracked with the presence of widespread plaques. The findings may provide clues to what kicks off the earliest stages of disease.
- Suzanne Hendrix on In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period.
- Richard C. Mohs on Next Up for Human Brain Imaging: Synaptic Density?
- Roberto Malinow on Next Up for Human Brain Imaging: Synaptic Density?
- Stephen Salloway on Next Up for Human Brain Imaging: Synaptic Density?
- P. Murali Doraiswamy on Next Up for Human Brain Imaging: Synaptic Density?
- Chester Mathis on Next Up for Human Brain Imaging: Synaptic Density?
- Ilya Bezprozvanny on Shielding Synaptic Glutamate Receptor from Aβ Preserves Memory in Mice
- Roger Barker on Brexit Could Threaten Neurodegenerative Disease Research in Europe
- Michelle Mielke on Brain Trauma Linked to Parkinson’s, Not Alzheimer’s
- Pat McGeer on Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.
- Eric Blalock on Transcriptional signatures of brain aging and Alzheimer's disease: What are our rodent models telling us?
- Nick Martin on Are Early Harbingers of Alzheimer’s Scattered Across the Genome?
- Walter A. Rocca on A Rising Tide of Parkinson’s?
- Gordon Wilcock on Brexit Could Threaten Neurodegenerative Disease Research in Europe
- Johnathan Cooper-Knock on Paper Alert: Autoimmunity in Another C9ORF72-Deficient Mouse Strain
- Alan Evans on LOAD of Data Place Vascular Malfunction as Earliest Event in Alzheimer’s
- Christian Haass on CAP Articulates Plan for Sharing Data from Trials of Preclinical Alzheimer’s Disease
- Ling Li on LOAD of Data Place Vascular Malfunction as Earliest Event in Alzheimer’s
- Barry Greenberg on LOAD of Data Place Vascular Malfunction as Earliest Event in Alzheimer’s
- Torik Ayoubi on LOAD of Data Place Vascular Malfunction as Earliest Event in Alzheimer’s
- Takaomi Saido on Brexit Could Threaten Neurodegenerative Disease Research in Europe